Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol

Author:

Zhang Yiyi1,Dron Jacqueline S.23,Bellows Brandon K.1,Khera Amit V.245,Liu Junxiu6,Balte Pallavi P.1,Oelsner Elizabeth C.1,Amr Sami Samir78,Lebo Matthew S.78,Nagy Anna8,Peloso Gina M.9,Natarajan Pradeep2410,Rotter Jerome I.11,Willer Cristen121314,Boerwinkle Eric15,Ballantyne Christie M.16,Lutsey Pamela L.17,Fornage Myriam18,Lloyd-Jones Donald M.19,Hou Lifang19,Psaty Bruce M.202122,Bis Joshua C.20,Floyd James S.2021,Vasan Ramachandran S.232425,Heard-Costa Nancy L.26,Carson April P.27,Hall Michael E.27,Rich Stephen S.28,Guo Xiuqing11,Kazi Dhruv S.429,de Ferranti Sarah D.3031,Moran Andrew E.1

Affiliation:

1. Division of General Medicine, Columbia University, New York, New York

2. Cardiovascular Disease Initiative, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge

3. Center for Genomic Medicine, Massachusetts General Hospital, Boston

4. Department of Medicine, Harvard Medical School, Boston, Massachusetts

5. Division of Cardiology, Brigham and Women’s Hospital, Boston, Massachusetts

6. Department of Population Health Science and Policy, Icahn School of Medicine, Mount Sinai, New York, New York

7. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

8. Laboratory for Molecular Medicine, Personalized Medicine, Mass General Brigham, Cambridge, Massachusetts

9. Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts

10. Department of Medicine, Massachusetts General Hospital, Boston

11. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California

12. Department of Internal Medicine, University of Michigan, Ann Arbor

13. Department of Human Genetics, University of Michigan, Ann Arbor

14. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor

15. Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston

16. Department of Medicine, Baylor College of Medicine, Houston, Texas

17. Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis

18. The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston

19. Northwestern University, Chicago, Illinois

20. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle

21. Department of Epidemiology, University of Washington, Seattle

22. Department of Health Systems and Population Health, University of Washington, Seattle

23. The Framingham Heart Study, Framingham, Massachusetts

24. Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, Massachusetts

25. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts

26. Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts

27. Department of Medicine, University of Mississippi Medical Center, Jackson

28. Center for Public Health Genomics, University of Virginia, Charlottesville

29. Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts

30. Department of Cardiology, Boston Children’s Hospital, Boston, Massachusetts

31. Department of Pediatrics, Harvard Medical School, Boston, Massachusetts

Abstract

ImportanceFamilial hypercholesterolemia (FH) is a genetic disorder that often results in severely high low-density lipoprotein cholesterol (LDL-C) and high risk of premature coronary heart disease (CHD). However, the impact of FH variants on CHD risk among individuals with moderately elevated LDL-C is not well quantified.ObjectiveTo assess CHD risk associated with FH variants among individuals with moderately (130-189 mg/dL) and severely (≥190 mg/dL) elevated LDL-C and to quantify excess CHD deaths attributable to FH variants in US adults.Design, Setting, and ParticipantsA total of 21 426 individuals without preexisting CHD from 6 US cohort studies (Atherosclerosis Risk in Communities study, Coronary Artery Risk Development in Young Adults study, Cardiovascular Health Study, Framingham Heart Study Offspring cohort, Jackson Heart Study, and Multi-Ethnic Study of Atherosclerosis) were included, 63 of whom had an FH variant. Data were collected from 1971 to 2018, and the median (IQR) follow-up was 18 (13-28) years. Data were analyzed from March to May 2023.ExposuresLDL-C, cumulative past LDL-C, FH variant status.Main Outcomes and MeasuresCox proportional hazards models estimated associations between FH variants and incident CHD. The Cardiovascular Disease Policy Model projected excess CHD deaths associated with FH variants in US adults.ResultsOf the 21 426 individuals without preexisting CHD (mean [SD] age 52.1 [15.5] years; 12 041 [56.2%] female), an FH variant was found in 22 individuals with moderately elevated LDL-C (0.3%) and in 33 individuals with severely elevated LDL-C (2.5%). The adjusted hazard ratios for incident CHD comparing those with and without FH variants were 2.9 (95% CI, 1.4-6.0) and 2.6 (95% CI, 1.4-4.9) among individuals with moderately and severely elevated LDL-C, respectively. The association between FH variants and CHD was slightly attenuated when further adjusting for baseline LDL-C level, whereas the association was no longer statistically significant after adjusting for cumulative past LDL-C exposure. Among US adults 20 years and older with no history of CHD and LDL-C 130 mg/dL or higher, more than 417 000 carry an FH variant and were projected to experience more than 12 000 excess CHD deaths in those with moderately elevated LDL-C and 15 000 in those with severely elevated LDL-C compared with individuals without an FH variant.Conclusions and RelevanceIn this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3